Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: The molecular mechanism and the clinical application

British Journal of Dermatology

Volumn 160, Issue 4, 2009, Pages 887-889

  Lee, J H ^a,b   Cheng, A L ^a,b   Lin, C W ^a   Kuo, S H ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anaplastic large cell lymphoma; NF B; Thalidomide; Tumour necrosis factor

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; CHLORAMBUCIL; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOTRETINOIN; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; DISEASE FREE SURVIVAL; DRUG MECHANISM; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN NODULE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL; MALE; MIDDLE AGED; NF-KAPPA B; REMISSION INDUCTION; SKIN NEOPLASMS; THALIDOMIDE;

EID: 62649139101     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09042.x     Document Type: Article

References (10)

1. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 2003 40 : 244 56.
2. Paulli M, Berti E, Rosso R et al. CD30/Ki-1-positive lymphoproliferative disorder of the skin - clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer cutaneous lymphoma project group. J Clin Oncol 1995 13 : 1343 54.
3. Shehan JM, Kalaaji AN, Markovic SN et al. Management of multifocal primary cutaneous CD30+ anaplastic large cell lymphoma. J Am Acad Dermatol 2004 51 : 103 10.
4. Chou WC, Su IJ, Tien HF et al. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid. Cancer 1996 78 : 1805 12.
5. Horie R, Watanabe M, Ishida T et al. The NMP-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell 2004 5 : 353 64.
6. Keifer JA, Guttridge DC, Ashburner BP et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001 276 : 22382 7.
7. Mileshkin L, Biagi JJ, Mitchell P et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003 102 : 69 77.
8. Damaj G, Bouabdallah R, Vey N et al. Single-agent thalidomide induces response in T-cell lymphoma. Eur J Hematol 2005 74 : 169 71.
9. Yeh PY, Kuo SH, Yeh KH et al. A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus. J Biol Chem 2006 281 : 167 75.
10. Mathas S, Johrens K, Joos S et al. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005 106 : 4287 93.